ALTSTATION.IO

The Cigna Group (CI) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$292.00

Change

+2.63%

Market Cap

$78.00B

Avg Volume

1.8M

Company Overview

The Cigna Group, based in Bloomfield, Connecticut, offers a variety of insurance and health-related services. Its main segments include Cigna Healthcare, which provides medical, pharmacy, dental, behavioral health, and Medicare plans, and Evernorth Health Services, which focuses on coordinated health solutions like pharmacy benefits and care management. The company serves a wide range of customers, including individuals, employers, health plans, and government organizations.

Cigna is a market leader in the healthcare insurance sector, competing directly with major players like UnitedHealth Group and Anthem. Its edge comes from a comprehensive range of services, notably its emphasis on integrated health solutions through Evernorth. However, the company faces challenges from rising healthcare costs and regulatory pressures, which could impact margins. The competitive landscape is also evolving, with a trend towards value-based care, which Cigna is addressing but must continually adapt to remain relevant.

Currently, Cigna is in a growth phase, bolstered by strategic investments in health technology and digital services. The rebranding to The Cigna Group in February 2023 reflects its commitment to a broader healthcare strategy. Recent milestones include expanding Evernorth’s service offerings, which should drive further growth in a market looking for more integrated health solutions. Overall, the company is positioning itself well to capitalize on new opportunities in the healthcare space.

Key Financials

Market Cap

$78.00B

Revenue

$274.90B

EBITDA

$12.90B

Gross Margin

9.3%

Profit Margin

2.2%

Revenue Growth

10.4%

Total Cash

$8.73B

Total Debt

$31.46B

Free Cash Flow

$10.60B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

13.16

Forward P/E

8.73

Beta

0.28

52-Week High

$350.00

52-Week Low

$239.51

EPS

$22.19

50-Day Avg

$274.61

200-Day Avg

$294.64

Price/Book

1.87

Technical Analysis

Over the past 52 weeks, The Cigna Group (CI) has exhibited a primarily sideways trend, with minor fluctuations around the $290 level, reflecting a 1.8% increase. Key support is identified around $280, where price action consistently bounced back in October and December, while resistance is found near the $320 range reached in February. Throughout this period, notable price formations include a high volatility range between March and May followed by a pronounced downward movement from June to October, resulting in a bottom formation that suggests potential accumulation. Recently, there has been a bullish momentum with the price pushing towards the current level of $292, which is just below the mid-range of the 52-week data, indicating consolidation. This positioning suggests the stock is currently neither overbought nor oversold, making it potentially stable for future upside if it can break through the $300 resistance. Overall, the stock’s stability around this level may attract attention from both buyers and sellers as it navigates its next move.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for The Cigna Group (CI) stock in the past week, from February 1 to February 7, 2026:

1. Cigna Group Exceeds Q4 2025 Earnings Estimates and Issues 2026 Guidance, Increases Dividend

The Cigna Group announced its fourth-quarter and full-year 2025 results on Thursday, February 5, 2026, reporting adjusted earnings per share (EPS) of $8.08, surpassing the consensus estimate of $7.90. The company’s revenue for the quarter reached $72.50 billion, exceeding analyst estimates of $69.53 billion. For the full year 2025, adjusted revenue was $275 billion with adjusted EPS of $29.84. Looking ahead, Cigna Group established its FY 2026 guidance with an adjusted EPS forecast of at least $30.25 and anticipates approximately $280 billion in adjusted revenue. In a show of confidence, the board also raised the quarterly dividend to $1.56 per share.

2. FTC Settles Litigation with Express Scripts Over Insulin Drug Pricing

On February 4, 2026, the Federal Trade Commission (FTC) announced a settlement with Cigna’s pharmacy benefit manager (PBM), Express Scripts, concerning insulin drug pricing practices. This regulatory agreement resolves PBM matters, including the insulin case, and is expected to deliver approximately $7 billion in out-of-pocket relief over 10 years, providing crucial regulatory clarity that aligns with Cigna’s new rebate-free PBM model. Cigna plans to implement this model for its fully insured business in 2027 and for at least 50% of Evernorth by the end of 2028.

Market Sentiment and Analyst Recommendations

Bull Case

Cigna just beat Q4 earnings by 2.3% and revenue by 4.3%, then guided 2026 EPS to $30.25 minimum — a 1.4% raise from 2025’s $29.84. The stock trades at 13.16x P/E on $274.9B revenue, which is cheap for a company growing revenue at 10.4% and generating $8.73B in cash. The FTC settlement on insulin pricing actually removes regulatory overhang and clarifies the path forward for the rebate-free PBM model, which should improve margins when fully deployed by 2028. Analysts are nearly unanimous — 46 buy ratings, zero sells, with a $323.84 average target implying 10.9% upside from here. The dividend just got raised to $1.56 quarterly, signaling management confidence. The stock is consolidating right at the $280-$320 range after a 52-week bottom formation, positioning it for a breakout above $300 resistance with room to run toward the $350 high.

Bear Case

Cigna carries $31.46B in debt against $8.73B in cash, a 3.6x net debt position that limits financial flexibility if healthcare reform accelerates or margins compress. The PBM business is under sustained political and regulatory pressure — the $7B insulin relief package is real money over 10 years, and the rebate-free model won’t fully deploy until 2027-2028, leaving two years of uncertainty. Revenue growth of 10.4% is solid but masks potential margin pressure from the transition; the company hasn’t detailed the earnings impact of moving to the new model. Valuation has re-rated higher recently on earnings beat momentum, and at 13.16x P/E the stock is no longer deeply discounted relative to healthcare peers. The 52-week chart shows the stock is still 16.6% below its $350 high from earlier this year, suggesting buyers got burned on the recent rally. Macro headwinds around healthcare costs and potential drug pricing legislation remain a persistent overhang.

What to Watch

Monitor Q1 2026 earnings in late April for signs that the rebate-free PBM transition is tracking as expected — any guidance cut or margin miss would signal execution risk. Watch the $300 level closely; a sustained break above that opens the path toward $320 and the analyst target of $328. Track Evernorth segment performance specifically, since that’s where the PBM model shifts will matter most; look for commentary on customer retention and pricing power. The 2027 PBM implementation for fully insured business is the real catalyst — any delays or customer pushback would be a red flag. Keep an eye on healthcare legislation around drug pricing and PBM reform; a major bill could force faster or more aggressive changes than Cigna’s current timeline. Finally, monitor the debt-to-cash ratio over the next two quarters; if the company starts deploying cash aggressively for M&A or buybacks, that could either accelerate growth or increase financial risk depending on deal quality.

Analyst Consensus

BUY

Based on 23 analyst opinions

Low Target

$290.15

Mean Target

$328.22

High Target

$378.00

Earnings and Financial Data

Sector

Healthcare

Industry

Healthcare Plans

Employees

N/A

Earnings & Dividends

Next Earnings

Feb 05, 2026

EPS (Trailing)

$22.19

Dividend Yield

219.0%

Payout Ratio

27.2%

Frequently Asked Questions

Is CI a good stock to buy?

Yes, analysts have a consensus recommendation of “BUY” for Cigna Group (CI) with a price target of $328.22. Given its P/E ratio of 13.16 and strong market cap of $78.00B, it appears undervalued compared to its peers.

What is CI’s price target?

The target price for Cigna Group is set at $328.22. This represents a potential upside of 12.5% from the current price of $292.00.

Does CI pay a dividend?

Yes, Cigna Group offers a significant dividend yield of 219.0%. This makes it an attractive proposition for income-focused investors, though it’s essential to verify the sustainability of this yield.

What are CI’s recent stock performance numbers?

The stock has traded in a 52-week range of $239.51 to $350.00. This volatility suggests potential investment opportunities, especially at the lower end of this range.

How does CI compare to its peers in the healthcare sector?

With a forward P/E of 8.73, Cigna Group appears competitively priced against other healthcare plans. The combination of solid earnings potential and a lower P/E ratio makes it an appealing choice in this sector.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.